VEGF expression is associated with negative estrogen receptor status in patients with breast cancer

International Journal of Surgical Pathology

Volumn 14, Issue 1, 2006, Pages 49-55

  Fučkar, Dora ^a   Dekanić, Andrea ^a   Štifter, Sanja ^a   Mustać, Elvira ^a   Krstulja, Mira ^a   Dobrila, Fran ^b   Jonjić, Nives ^a  

^a UNIVERSITY OF RIJEKA   (Croatia)

^b KBC RIJEKA   (Croatia)

Author keywords

Breast neoplasm; Estrogen; Immunohistochemistry; Postmenopause; Premenopause; Receptors; Vascular endothelial growth factor A

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; VASCULOTROPIN;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; ESTROGEN ACTIVITY; FEMALE; HISTOPATHOLOGY; HORMONE RECEPTOR INTERACTION; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; MENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE DIAGNOSIS; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPH NODES; MENOPAUSE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 32344439001     PISSN: 10668969     EISSN: None     Source Type: Journal    
DOI: 10.1177/106689690601400109     Document Type: Article

References (30)

1. Feige JJ, Bailly S. Molecular bases of angiogenesis. Bull Acad Natl Med 184:537-544, 2000
2. Plate KH, Breier G, Risau W. Molecular mechanisms of developmental and tumor angiogenesis. Brain Pathol 3:207-218, 1994
3. Jahroudi N, Greenberger JS. The role of endothelial cells in tumor invasion and metastasis. J Neurooncol 23:99-108, 1995
4. Senger DR, Van De Water L, Brown LF, Nagy JA, Yeo T-K, Berse B, Jackman RW, Dvorak AM, Dvorak HF. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 12:303-324, 1993
5. Breier G, Clauss M, Risau W. Coordinate expression of vascular endothelial growth factor receptor-1 (flt-1) and its ligands suggests a paracrine regulation of murine vascular development. Dev Dyn 204:228-239, 1995
6. Tomanek RJ, Ratajska A, Kitten GT, Yue X, Sandra A. Vascular endothelial growth factor expression coincides with coronary vasculogenesis and angiogenesis. Dev Dyn 61:215-254, 1999
7. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 18:4-25, 1997
8. Quentin T, Schlott T, Korabiowska M, Kathei N, Zoller G, Glaser F, Kunze E. Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression. Anticancer Res 24(5A):2745-2756, 2004
9. Celen O, Kahraman I, Yildirim E, Berberoglu U. Correlation of vascular endothelial growth factor (VEGF) and CEA with clinicopathological variables in colorectal cancer patients. Neoplasma 51:293-299, 2004
10. Zhou YJ, Xiong YX, Wu XT, Shi D, Fan W, Zhou T, Li YC, Huang X. Inactivation of PTEN is associated with increased angiogenesis and VEGF overexpression in gastric cancer. World J Gastroenterol 10:3225-3229, 2004
11. Yamakawa M, Liu LX, Belanger AJ, Date T, Kuriyama T, Goldberg MA, Cheng SH, Gregory RJ, Jiang C. Expression of angiopoietins in renal epithelial and clear cell carcinoma cells: Regulation by hypoxia and participation in angiogenesis. Am J Physiol Renal Physiol 287:F649-F657, 2004
12. Mohamed KM, Le A, Duong H, Wu Y, Zhang Q, Messadi DV. Correlation between VEGF and HIF-1alpha expression in human oral squamous cell carcinoma. Exp Mol Pathol 76:143-152, 2004
13. Gupta K, Radotra BD, Banerjee AK, Nijhawan R. Quantitation of angiogenesis and its correlation with vascular endothelial growth factor expression in astrocytic tumors. Anal Quant Cytol Histol 26:223-229, 2004
14. Beppu K, Jaboine J, Merchant MS, Mackall CL, Thiele CJ. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst 96:46-55, 2004
15. Elson CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 19:403-410, 1991
16. Valkovic T, Dobrila F, Melato M, Sasso F, Rizzardi C, Jonjic N. Correlation between vascular endothelial growth factor, angiogenesis, and tumor-associated macrophages in invasive ductal breast carcinoma. Virchows Arch 440:583-588, 2002
17. Ali SH, O'Donnell AL, Balu D, Pohl MB, Seyler MJ, Mohamed S, Mousa S, Dandona P. Estrogen receptor alpha in the inhibition of cancer growth and angiogenesis. Cancer Res 60:7094-7098, 2000
18. Bausero P, Ben-Mahdi MH, Mazucatelli JP, Bloy C, Perrot-Applanat M. Vascular endothelial growth factor is modulated in vascular muscle cells by estradiol, tamoxifen, and hypoxia. Am J Physiol Heart Circ Physiol 279:H2033-H2042, 2000
19. Takei H, Lee ES, Jordan VC. In vitro regulation of vascular endothelial growth factor by estrogens and antiestrogens in estrogen-receptor positive breast cancer. Breast Cancer 9:39, 2002
20. Linderholm B, Tavelin B, Grankvist K, Henriksson R. CD 31, vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (BFGF) discriminate between subgroups of 827 patients-different angiogenic pathways in human breast cancer? 2000 ASCO Annual Meeting, Abstract number 2546
21. Foekens JA, Peters HA, Grebenchtchikov N, Look MP, Meijer-van Gelder ME, Geurts-Moespot A, van der Kwast TH, Sweep CGJ, Klijn JGM. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 61:5407-5414, 2001
22. Ludovini V, Sidoni A, Pistola L, Bellezza G, De Angelis V, Gori S, Mosconi AM, Bisagni G, Cherubini R, Bian AR, Rodino C, Sabbatini R, Mazzocchi B, Bucciarelli E, Tonato M, Colozza M. Evaluation of the prognostic role of vascular endothelial growth factor and microvessel density in stages I and II breast cancer patients. Breast Cancer Res Treat 81:159-168, 2003
23. Kamal H, Kumar H, Read JR, Fox JN, Monson JRT, Kerin MJ. Serum vascular endothelial growth factor in breast cancer: Its relation with cancer type and estrogen receptor status. Clin Can Res 7:3491-3494, 2001
24. Dreisbach LP, Ianonne M, Vahedian M, McGrain A, Villar H, Bellamy W, Stopeck A. Vascular endothelial growth factor (VEGF) plasma levels and tumor expression in breast cancer: A comparison of random preoperative VEGF plasma levels in malignant and benign breast disease. ASCO Annual Meeting. 2002; Abstract number 2986
25. Nishimura R, Nagao K, Miyayama H, Matsuda M, Baba K, Yamashita H, Fukuda M. Higher plasma vascular endothelial growth factor levels correlate with menopause, overexpression of p53, and recurrence of breast cancer. Breast Cancer 10:120-128, 2003
26. Yang W, Klos K, Yang Y, Smith TL, Shi D, Yu D. ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. Cancer 94:2855-2861, 2002
27. Shannon C, Smith IE. Breast cancer in adolescents and young women. Eur J Cancer 39:2632-2642, 2003
28. Linderholm B, Andersson J, Lindh B, Beckman L, Erlanson M, Edin K, Tavelin B, Grankvist K, Henriksson R. Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment. Eur J Cancer 40:33-42, 2004
29. Konecny GE, Meng YG, Untch M, Wang HJ, Bauerfeind I, Epstein M, Stieber P, Vernes JM, Gutierrez J, Hong K, Beryt M, Hepp H, Slamon DJ, Pegram MD. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 10:1706-1716, 2004
30. Ragaz J, Miller K, Badve S, Dayachko Y, Dunn S, Nielsen T, Brodie A, Huntsman D, Bajdik C, Sledge G. Adverse association of expressed vascular endothelial growth factor (VEGF) with long-term outcome of stage I-III breast cancer (BrCa), with co-expression data of VEGF and Her2, Cox2, uPA and ER. Results from the British Columbia Tissue Microarray Project, J Clin Oncol ASCO Annual Meeting Proceedings (Postmeeting Edition) 22:524, 2004